Advanced Filters
noise

idiopathic-membranous-nephropathy Clinical Trials

A listing of idiopathic-membranous-nephropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 28 clinical trials

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

18 - 75 years of age All Phase 2

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy

18 - 80 years of age All Phase 2/3

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

18 - 70 years of age All Phase 2
R Ruben Visch, M.D.

Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study

Objective: To assess the disappearance rate (half-life) of anti-PLA2R antibodies in high-risk primary membranous nephropathy (pMN) patients treated with obinutuzumab (OBI), and to evaluate immunological and clinical remission, adverse events, and quality of life. Design: Open-label, single-center, prospective pilot intervention study conducted at Radboud University Medical Center. Population: 20 adult …

18 years of age All Phase 2/3

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in …

18 years of age All Phase 3

A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

18 - 75 years of age All Phase 2/3
Q Qiong Wen

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group. Intervention group was given rituximab combined with corticosteroids in induction therapy and the control group was given rituximab monotherapy. After 6 months, patients who had decreased 24h …

18 - 75 years of age All Phase 4
J Jipeng Li

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital. Prior to receiving CAR-T cell therapy, patients will undergo lymphodepletion chemotherapy with cyclophosphamide (fludarabine will be added if necessary). After prophylactic administration …

18 years of age All Phase 1

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type …

18 - 80 years of age All Phase 3
H Heng Li

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

18 - 75 years of age All Phase 1

Simplify language using AI